Last quarter (Q4 2023), Genmab's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Genmab's net income was $―. See Genmab’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 7.25B	$ 16.47B	$ 14.51B	$ 8.48B	$ 10.11B	$ 5.39B
Cost of Revenue	$ ―	$ 226.00M	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ 16.25B	$ 14.51B	$ ―	$ ―	$ ―
Operating Expense	$ 4.07B	$ 10.93B	$ 8.24B	$ 5.46B	$ 3.80B	$ 2.59B
Operating Income	$ 3.18B	$ 5.32B	$ 6.27B	$ 3.02B	$ 6.31B	$ 2.80B
Net Non Operating Interest Income Expense	$ 1.33B	$ 1.21B	$ 1.00B	$ 184.00M	$ 174.00M	$ 113.00M
Other Income Expense	$ 1.25B	$ ―	$ 659.00M	$ 781.00M	$ -583.00M	$ -46.00M
Pretax Income	$ 5.76B	$ 5.64B	$ 8.30B	$ 3.98B	$ 5.90B	$ 2.88B
Tax Provision	$ 1.29B	$ 1.28B	$ 1.49B	$ 975.00M	$ 1.15B	$ 719.00M
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ 4.47B	$ 4.35B	$ 6.81B	$ 3.01B	$ 4.76B	$ 2.17B
Basic EPS	$ ―	$ 66.64	$ 83.38	$ ―	$ ―	$ 3.44
Diluted EPS	$ ―	$ 66.02	$ 82.59	$ ―	$ ―	$ 3.40
Basic Average Shares	$ ―	$ 65.31M	$ 65.39M	$ ―	$ ―	$ 629.63M
Diluted Average Shares	$ ―	$ 65.91M	$ 66.01M	$ ―	$ ―	$ 636.37M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 4.07B	$ 11.15B	$ 8.24B	$ 5.46B	$ 3.80B	$ 2.59B
Net Income From Continuing And Discontinued Operation	$ 4.47B	$ 4.35B	$ 6.81B	$ 3.01B	$ 4.76B	$ 2.17B
Normalized Income	$ 3.49B	$ 4.14B	$ 6.10B	$ 2.42B	$ 5.23B	$ 2.08B
Interest Expense	$ 206.00M	$ ―	$ ―	$ 13.00M	$ 10.00M	$ 7.00M
EBIT	$ 5.97B	$ 5.66B	$ 8.28B	$ 4.00B	$ 5.91B	$ 2.87B
EBITDA	$ 5.97B	$ 5.96B	$ 8.65B	$ 4.24B	$ 6.17B	$ 3.00B

Currency in USD

Genmab Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing